Evidence map›Paper›PMID 40781175›Full record

ArticleEuropean journal of pediatrics2025

Clinical, laboratory and molecular features of glycogen storage disease type 1a and 1b patients from Turkey: novel mutations and phenotypes.

Ayşe Akyüz, İlyas Okur, Leyla Tümer, Fatma Tuba Eminoğlu, Engin Köse, Filiz Başak Ergin, Aslı İnci, Buket Dalgıç, Burcu Yüce, Bahattin Çiftçi and 7 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Ayşe AkyüzDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey. aysheakyz@gmail.com.ORCID http://orcid.org/0000-0002-0647-3138
İlyas OkurDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Leyla TümerDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Fatma Tuba EminoğluDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey.
Engin KöseDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey.
Filiz Başak ErginDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Aslı İnciDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Buket DalgıçDepartment of Pediatrics, Department of Pediatric Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Burcu YüceDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Bahattin ÇiftçiDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Suna Özhan OktarDepartment of Radiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Gonca ErbaşDepartment of Radiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Gürsel BiberoğluDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Murat ÖktemDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Sevcan A BakkaloğluDepartment of Pediatrics, Department of Pediatric Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Emine AktaşDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Fatih Süheyl EzgüDepartment of Pediatrics, Department of Inborn Metabolic Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycogen storage disease type 1 (GSD1), which is categorized into GSD1a and GSD1b, is caused by disease-causing genetic variants in G6PC or SLC37A4 genes, respectively. The aim of this study was to present clinical characteristics, novel phenotypic and molecular features as well as long-term complications of the largest cohort of patients in Turkey and one of the largest cohorts in the world. The demographic, clinical, and molecular data of GSD1a or 1b patients who were followed up between 2000 and 2024 were collected retrospectively from patients' medical records. A total of 39 GSD1a patients were enrolled, and four different variants in the G6PC gene, c.247C > T (p.R83C), c.809G > T (p.G270V), c.562G > C (p.G188R), c.480G > A (p.W160*) were revealed. The most common variant among Turkish GSD1a patients was the c.247C > T (p.R83C) variant with an allele frequency of about 90%. Some unusual clinical features such as stroke, cataract, and mental retardation were observed in some patients. Also, cardiac hypertrophy was detected in three patients. Six different variants in the SLC37A4 gene, c.1042_1043delCT (p.L348Vfs*53), c.892_905del (p.N298Pfs*23), c.1015G > T (p.G339C), c.817G > A (p.G273S), c.892A > G (p.N298D), and c.382 T > C (p.W128R) were detected in eight patients with GSD1b, of which c.892A > G (p.N298D) and c.892_905del (p.N298Pfs*23) were novel. The most prevalent variant was c.1042_1043delCT (p.L348Vfs*53). The patient with the novel variant c.892A > G (p.N298D) has shown a very mild clinical course and was diagnosed in adulthood. This patient also had a co-existing HNF1A variants causing hepatic adenomas and MODY Diabetes.

conclusionsBased on our study with the largest cohort from Turkey, the c.247C > T (p.R83C) allele frequency was found to be 85% for GSD1a, resembling the Ashkenazi Jewish population. The most frequent pathogenic genetic variant for GSD1b was found to be c.1042_1043delCT (p.L348Vfs*53). There were patients with novel presentations and coexistent phenotypic features. The high frequency of consanguineous marriages, of course, significantly contributes to such molecular and clinical findings, but further studies are obviously needed to investigate other factors. WHAT IS KNOWN: • Glycogen storage disease type 1 (GSD1), which is categorized into GSD1a and GSD1b, is an autosomal recessive inborn error of metabolism, caused by disease-causing genetic variants in G6PC or SLC37A4 genes. The allelic homogeneity of G6PC gene was described in some ethnic or geographical origin. • Without adequate treatments long term complications may present in both GSD1a and GSD1b. WHAT IS KNOWN: • This study documented the genotypic background and showed that c.247C>T (p.R83C) pathogenic genetic variant allele frequency is very high in Turkey for GSD1a resembling the Ashkenazi Jewish population and the c.1042_1043delCT (p.L348Vfs*53) disease-causing genetic variant seems to be the most frequent one for GSD1b. • This study includes largest cohort from Turkey with a high frequency of consanguineous marriages, and also presents phenotypic and genotypic features, co-existent diseases or conditions that could modify the clinical course.

Indexed as

Glucose-6-PhosphataseGlycogen Storage Disease Type IMutationAdolescentAntiportersChildChild, PreschoolFemaleHumansInfantMaleMonosaccharide Transport ProteinsPhenotypeRetrospective StudiesTurkeyAntiportersGlucose-6-PhosphataseMonosaccharide Transport ProteinsSLC37A4 protein, humanGlucose-6-phosphataseGlucose-6-phosphate transporterGlycogen storage disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.